

## Special Issue

# Cancer Epigenetics-Recent Developments in Epigenetic Diagnostics and Therapy

### Message from the Guest Editor

The field of cancer epigenetics has flourished in the past twenty years, and our knowledge and understanding of epigenetic abnormalities has expanded enormously. DNA methylation-based cancer biomarkers were successfully developed and introduced into clinical practice. The complexity of epigenetic phenomena, which emerges from epigenomic studies, leads to new questions about the basic mechanisms of action of the epigenetic machinery and the mechanisms of its dysregulation in cancer.

I hope that this Special Issue on Cancer Epigenetics will be a creative space for presenting the results of novel studies and exchanging ideas about the significance of DNA methylation and histone modifications in cancer. What is needed is in-depth synthesis of current knowledge, but also marking the unknown terrain in the field, in order to be able to ask the right questions in the future. Therefore, you are invited to contribute to this discussion.

---

### Guest Editor

Dr. Jarosław Paluszczak

Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 3, Rokietnicka Street, 60-806 Poznań, Poland

---

### Deadline for manuscript submissions

closed (15 August 2021)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/54950](https://mdpi.com/si/54950)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))